Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

McMaster University

$107,100.00

An Individual Participant Data Meta-Analysis of Two Randomized Controlled Trials Assessing Oral Anticoagulation for Device-detected Atrial Fibrillation: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) and Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH AFNET 6) (ARTESiA-NOAH IPDMA)

EF 2024-25

Résumé
Atrial fibrillation (AF) is the most common form of irregular heart beat and a major cause of disabling strokes. Blood thinners called 'oral anticoagulants' reduce the risk of stroke from AF. AF is usually diagnosed up when patients have symptoms, such as heart racing, or visit their doctor for a check-up and have an ECG. Patients with pacemakers and other heart rhythm devices often have AF picked up by the device. When a pacemaker makes the diagnosis of AF in a patient without symptoms, we are not sure if it carries the same stroke risk as AF diagnosed by ECG and if patients with pacemaker-detected AF will benefit from oral anticoagulant drugs. Two large international randomized clinical trials recently tested anti-coagulation drugs for patients with pacemaker-detected AF. The Canadian-led ARTESiA Study tested the anti-coagulant drug apixaban against aspirin in approximately 3500 patients. The German-led NOAH Study tested the anti-coagulant drug edoxaban against placebo in approximately 2500 patients. A combined analysis using overall study data showed that anti-coagulant drugs are effective in reducing stroke, but increase bleeds. There is a need to identify subgroups of patients that will benefit most. We will pool data from individual participants in ARTESiA and NOAH. This will form a new, large data set that will be capable of answering questions that the individual trials could not address. With the combined set, we examine specific subgroups of patients (e.g. men vs women, elderly patients and patients with kidney disease) and be able to do analyses to look at the threshold duration of pacemaker detected AF episodes that increase a patient's risk. Research funds are required to build a new combined database that harmonizes data from both studies and complies with international data privacy laws, to fund the salaries of statisticians and biometric programmers working on the database and to support research fellows who will work on projects in the database.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
508879
Name
McIntyre William F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Clinical Investigation - D: Cardiovascular Systems
Projecttitle
An Individual Participant Data Meta-Analysis of Two Randomized Controlled Trials Assessing Oral Anticoagulation for Device-detected Atrial Fibrillation: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) and Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH AFNET 6) (ARTESiA-NOAH IPDMA)
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$107,100
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Atrial Fibrillation; Meta-Analysis; Pacemakers; Stroke
Abstract
Atrial fibrillation (AF) is the most common form of irregular heart beat and a major cause of disabling strokes. Blood thinners called 'oral anticoagulants' reduce the risk of stroke from AF. AF is usually diagnosed up when patients have symptoms, such as heart racing, or visit their doctor for a check-up and have an ECG. Patients with pacemakers and other heart rhythm devices often have AF picked up by the device. When a pacemaker makes the diagnosis of AF in a patient without symptoms, we are not sure if it carries the same stroke risk as AF diagnosed by ECG and if patients with pacemaker-detected AF will benefit from oral anticoagulant drugs. Two large international randomized clinical trials recently tested anti-coagulation drugs for patients with pacemaker-detected AF. The Canadian-led ARTESiA Study tested the anti-coagulant drug apixaban against aspirin in approximately 3500 patients. The German-led NOAH Study tested the anti-coagulant drug edoxaban against placebo in approximately 2500 patients. A combined analysis using overall study data showed that anti-coagulant drugs are effective in reducing stroke, but increase bleeds. There is a need to identify subgroups of patients that will benefit most. We will pool data from individual participants in ARTESiA and NOAH. This will form a new, large data set that will be capable of answering questions that the individual trials could not address. With the combined set, we examine specific subgroups of patients (e.g. men vs women, elderly patients and patients with kidney disease) and be able to do analyses to look at the threshold duration of pacemaker detected AF episodes that increase a patient's risk. Research funds are required to build a new combined database that harmonizes data from both studies and complies with international data privacy laws, to fund the salaries of statisticians and biometric programmers working on the database and to support research fellows who will work on projects in the database.
Competitiondate
202409
Approvedterm2
1 yr 0 mth
Pinamesdelim
McIntyre, William F
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $107,100~ $0~